Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety Extension of Ferric Citrate in ESRD
NCT01554982Phase 3Completed
- Sponsor
- Keryx Biopharmaceuticals, Inc.
- Start
- Aug 2012
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of ferric citrate in hyperphosphatemia, sponsored by Keryx Biopharmaceuticals, Inc. Primary endpoint: Safety Parameters at 48 weeks. Started Aug 2012; status: completed.
02
Drugs
ferric citrate
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT01554982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01554982.